Effective 1 de julio de 2022, diagnosis coding in the Fecal Calprotectin Testing policy will be edited to reflect that the testing is not covered for Medicare Advantage plans and not medically necessary for commercial products in the management of confirmed inflammatory bowel disease. Additional information pertaining to the medical policy can be found here.